Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice

Arthritis Care and Research

Volumn 64, Issue 5, 2012, Pages 640-647

  Anderson, Jaclyn ^a   Caplan, Liron ^c   Yazdany, Jinoos ^d   Robbins, Mark L ^e   Neogi, Tuhina ^f   Michaud, Kaleb ^b,g   Saag, Kenneth G ^h   O'Dell, James R ^b   Kazi, Salahuddin ⁱ  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^f BOSTON UNIVERSITY   (United States)

^g NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CHRONIC ARTHRITIS SYSTEMIC INDEX; CLINICAL DECISION MAKING; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEASIBILITY STUDY; HEALTH SURVEY; HUMAN; MEDICAL SCHOOL; PATIENT ACTIVITY SCALE 2; PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY; PRACTICE GUIDELINE; PROVIDER GLOBAL ASSESSMENT OF DISEASE ACTIVITY; PSYCHOMETRY; RATING SCALE; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX 5; RHEUMATOLOGY; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SIMPLIFIED DISEASE ACTIVITY INDEX; SYSTEMATIC REVIEW; VALIDATION STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HEALTH SURVEYS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84859853303     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21649     Document Type: Article

References (28)

1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
4. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
5. National Committee for Quality Assurance (NCQA), Physician Consortium for Performance Improvement (PCPI), Amer- ican College of Rheumatology (ACR). Rheumatoid arthritis physician performance measurement set. 2008. URL: http:// www.ama-assn.org/ama1/pub/upload/mm/pcpi/rheumatoidarthritis. pdf.
6. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology [editorial]. J Rheumatol 1998;25:198-9.
7. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, Disease Activity Score (DAS) and Disease Activity Score with 28-joint counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), patient-based Disease Activity Score with ESR (PDAS1) and patient-based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 2011;63 Suppl:S14-36.
8. Lansbury J. Quantitation of the activity of rheumatoid arthritis. 5. A method for summation of the systemic indices of rheumatoid activity. Am J Med Sci 1956;232:300-10.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
10. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410-5. (Pubitemid 41780656)
11. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to Disease Activity Score and Clinical Disease Activity Index categories. J Rheumatol 2008;35:2136-47.
12. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40. (Pubitemid 23175613)
13. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
14. Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004;50:3296-305. (Pubitemid 39372007)
15. Pincus T, Yazici Y, Bergman M. Development of a Multidimensional Health Assessment Questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol 2005;23 Suppl:S19-28. (Pubitemid 46661464)
16. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001;28:892-903. (Pubitemid 32246969)
17. Marhadour T, Jousse-Joulin S, Chales G, Grange L, Hacquard C, Loeuille D, et al. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). J Rheumatol 2010;37:932-7.
18. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48: 2750-62. (Pubitemid 37280602)
19. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42. (Pubitemid 36682360)
20. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82. (Pubitemid 28265410)
21. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis. Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-17. (Pubitemid 28505855)
22. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
23. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. (Pubitemid 36305610)
24. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
26. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006;24 Suppl:S29-32. (Pubitemid 44710278)
27. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011;63:43-52.
28. Hensor EM, Emery P, Bingham SJ, Conaghan PG. Discrepancies in categorizing rheumatoid arthritis patients by DAS- 28(ESR) and DAS-28(CRP): can they be reduced? Rheumatology (Oxford) 2010;49:1521-9.